15978-93-5Relevant academic research and scientific papers
A method for the treatment of tumor cell proliferative diseases of platinum (II) compound
-
Paragraph 0191; 0201; 0202; 0203, (2018/01/11)
Disclosed are a platinum compound with the leaving group malonic derivative "2" position substituent containing a primary amino, a secondary amino, a tertiary amino, and a quaternary amino, as well as pharmaceutically acceptable salt, preparation method thereof, and pharmaceutical composition containing the compound. Also disclosed are uses of the compound for treating cell proliferative diseases, particularly cancers. The platinum compound of the present invention has the high water solubility and the low toxicity.
Crystal structures of cis-diiododiammine platinum and trans-diazidodiammine platinum
Vasilchenko,Zadesenets,Baidina,Piryazev,Romanenko
, p. 1689 - 1692 (2018/02/09)
Platinum(II) complexes cis-[Pt(NH3)2I2] (1) and trans-[Pt(NH3)2(N3)2] (2) are structurally characterized separately for the first time. The crystallographic data are as follows: for 1, a = 7.0065(6) ?, b = 6.8714(6) ?, c = 7.4106(8) ?, β = 108.432(7)°, space group P21/m, Z = 2, ρcalc = 4.739 g/cm3; for 2, a = 8.1337(5) ?, b = 11.5821(7) ?, c = 6.9705(5) ?, β = 107.256(2)°, space group P21/c, Z = 4, ρcalc = 3.318 g/cm3. Platinum atoms have a square planar environment; the main structure-forming factor is the presence of intermolecular hydrogen bonds forming chain motifs in the structure of 1 and a threedimensional framework in the structure of 2.
METAL COMPLEX AND ANTICANCER AGENT CONTAINING THE SAME
-
Paragraph 0083, (2017/02/23)
PROBLEM TO BE SOLVED: To provide a platinum complex more excellent in anticancer activity than the coexisting platinum anticancer such as cisplatin and oxaliplatin, and also reduced in side-effects. SOLUTION: Provided is a platinum complex represented by formula (1) as a myo-inositol-1,2,3,4,5,6-hexakisphosphate derivative, and also provided is a platinum complex such as a (1,10-phenanthroline)(N-9-anthranilic methyl-1, 4-butane diamine) platinum [m and n respectively independently denote 1 or 2 and m+n denotes 3]. SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT
Synthesis, characterization, structures and cytotoxicity of platinum(II) complexes containing dimethylpyrazole based selenium ligands
Chopade, Suresh M.,Phadnis, Prasad P.,Hodage, Ananda S.,Wadawale, Amey,Jain, Vimal K.
supporting information, p. 72 - 80 (2015/02/19)
A series of water soluble platinum(II) complexes of general formulae [Pt(en)(L)][NO3]2, [Pt(NH3)2(L)][NO3]2 [en = ethylenediamine; L = dmpzC6H4Se(CH2)nCOOH or dmpzCH2CH2Se(CH2)nCOOH (n = 1 and 2)], [Pt(en)(L)][NO3][OH]·H2O [L = dmpzCH2CH2Se(CH2)nCOOH (n = 1 and 2)] and [Pt(dmpzCH2CH2SeCH2CH2COOH)2][Cl]2·2H2O have been synthesized. They were characterized by microanalyses, IR, NMR (1H, 13C{1H}, 77Se{1H} and 195Pt{1H}) spectroscopy. Molecular structures of [Pt(en)(dmpzCH2CH2SeCH2COOH)][NO3][OH]·H2O and [Pt(dmpzCH2CH2SeCH2CH2COOH)2][Cl]2·2H2O were determined unambiguously by single crystal X-ray diffraction analyses. The cytotoxicity of these complexes has been evaluated against human colon (HT29, Colo205), ovarian (A2780) and bladder (T24) cancer cell lines and compared with the activity of cisplatin and adriamycin.
PLATINUM COMPOUND HAVING AMINO OR ALKYLAMINO-CONTAINING SUCCINIC ACID DERIVATIVES AS LEAVING GROUP, PREPARTION METHOD THEREOF, AND USE THEREOF
-
Paragraph 0172; 0173, (2014/12/09)
Disclosed are a category of platinum compounds having amino- or alkylamino-containing succinato derivatives as leaving group, or pharmaceutically acceptable salts thereof, preparation method thereof, and medicinal compositions containing the compounds. Also disclosed is a use of the compounds in treating cell proliferative diseases, especially cancers. The platinum compounds of the present invention have high water solubility and small toxic side effect.
Peculiar features in the crystal structure of the adduct formed between cis-PtI2(NH3)2 and hen egg white lysozyme
Messori, Luigi,Marzo, Tiziano,Gabbiani, Chiara,Valdes, Amparo A.,Quiroga, Adoracion G.,Merlino, Antonello
supporting information, p. 13827 - 13829 (2014/01/06)
The reactivity of cis-diamminediiodidoplatinum(II), cis-PtI 2(NH3)2, the iodo analogue of cisplatin, with hen egg white lysozyme (HEWL) was investigated by electrospray ionization mass spectrometry and X-ray crystallography. Interestingly, the study compound forms a stable 1:1 protein adduct for which the crystal structure was solved at 1.99 A resolution. In this adduct, the PtII center, upon release of one ammonia ligand, selectively coordinates to the imidazole of His15. Both iodide ligands remain bound to platinum, with this being a highly peculiar and unexpected feature. Notably, two equivalent modes of PtII binding are possible that differ only in the location of I atoms with respect to ND1 of His15. The structure of the adduct was compared with that of HEWL-cisplatin, previously described; differences are stressed and their important mechanistic implications discussed.
INNERSPHERE AND STRUCTURE TRANSFORMATIONS IN DIAMINODIHALOPLATINITES ACCORDING TO NQR
Kravchenko, E. A.,Morgunov, V. G.,Gel'fman, M. I.
, p. 163 - 166 (2007/10/02)
Using NQR we have studied the complexes PtL2X2 (L= C5H5N, NH3, CH3NH2, C2H5NH2; X= Br, I).The formation of cis-isomers by these compounds was reported to be thermodynamically unfavourable (ref. 1) so they undergo cis-trans isomerization when heated.This w
